Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
filingDate |
2004-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5689b604a3663795254e077abf0a01a4 |
publicationDate |
2004-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2004223951-A1 |
titleOfInvention |
Combination therapy for cancer |
abstract |
A method for treating a human patient afflicted with cancer, is provided in which therapeutically effective amounts of temozolomide and pegylated interferon alpha are administered to such a patient. Also provided is a medical kit comprising: n (a) a supply of temozolomide; n (b) a supply of pegylated interferon alpha; and n (c) printed instructions for administering temozolomide and pegylated interferon alpha to a cancer patient. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006222792-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005187206-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010022609-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008306043-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008319039-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7615632-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009281078-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008081804-A1 |
priorityDate |
2000-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |